Clinical Trials Logo

Brain Edema clinical trials

View clinical trials related to Brain Edema.

Filter by:

NCT ID: NCT04116138 Completed - Glioblastoma Clinical Trials

Antisecretory Factor in Primary Glioblastoma 1

AFGBM1
Start date: September 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a non-randomised, open-label, single center-centre, Phase I-II study in patients with newly diagnosed glioblastoma. 5 patients with newly diagnosed glioblastoma are enrolled in the study and will receive an egg powder enriched for antisecretory factor (AF), Salovum, daily from 2 days before concomitant radio-chemo therapy until 14 days after finalisation.The primary aim of the study is to asses safety and feasibility of this regimen.

NCT ID: NCT03957837 Completed - Clinical trials for Intracranial Hypertension

Optical Nerve Sheath Changes During Head Down Laparoscopy

Start date: May 13, 2019
Phase:
Study type: Observational

Patient undergoing laparoscopic radical prostatectomy in steep trendelenburg position are at risk to develop complication from brain edema. Ultrasound assessment of optical nerve sheath diameter is a simply, non-invasive method to estimate the increase of intracranial pressure. It is unknown how optical nerve sheath diameter changes after prolonged head down position.

NCT ID: NCT03573999 Completed - Clinical trials for Metabolic Disturbance

Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation

Start date: June 29, 2018
Phase: Phase 4
Study type: Interventional

Usage of osmotic agents is a standard practice in neuroanesthesia since cerebral edema is a very common situation for patients with pathology in the brain. Cerebral edema is defined as the accumulation of fluid in the intracellular or extracellular compartments of the brain. Among other situations that have nothing to do with the brain, a supratentorial pathology such as a tumor, traumatic injury or an aneurysm, will lead to disruption of blood-brain barrier, and energy crisis of the cells that will cause mainly vasogenic and cytotoxic cerebral edema. The most common monitoring method for "measuring" cerebral edema is ICP (intracranial pressure) in which normal values are (with differences in the bibliography) 10-15 mmHg. The osmotic agents used most in neuroanesthesia are mannitol 20% and hypertonic NaCl 7.5% or 3%. Their brain relaxation effectiveness is supposed to be quite the same between the two different agents. Their main difference is that mannitol induces diuresis. Also, electrolyte disorders are another possibility after mannitol infusion. On the other hand, NaCl 7.5% causes vasodilation, does not induce diuresis and hemodynamically, even though it reduces SBP, it raises CO because of its excessive vasodilation. But both reduce cerebral edema due to the change of osmotic pressure in the vessels, that leads to extracting water from brain cells. A supratentorial craniotomy is de facto worsening the oxygenation and metabolism condition of the surgical site, adding to the problem the intracranial pathology causes in the first place. So if oxygen provided is low and the metabolic rate is high, the rate of anaerobic metabolism will raise. Measuring the oxygen in the jugular bulb is the most reliable monitoring method of cerebral oxygenation and metabolism. It becomes evident that optimization of cerebral oxygenation during a craniotomy will possibly affect the outcome of a patient, by improving it. So, if any superiority of one osmotic agent over the other could be demonstrated this will be very helpful in the decision making in routine clinical practice.

NCT ID: NCT03323580 Completed - Brain Tumor Clinical Trials

Effects of Intraoperative GDFT on the Postoperative Brain Edema

Start date: November 26, 2018
Phase: N/A
Study type: Interventional

Whether a fluid protocol aiming for protecting vital organ perfusion or fluid restriction is favorable to post-craniotomy outcomes such as brain edema remains uncertain. To our knowledge, there has been no extensive and quantitative analysis of brain edema following SVV-based GDFT in neurosurgical patients with malignant supratentorial glioma. So the study aims to observe the effect of the stroke volume variation-based GDFT on the postoperative brain edema and decrease the incidence of postoperative complications in neurosurgical patients with malignant supratentorial gliomas.

NCT ID: NCT03300648 Completed - Malaria, Cerebral Clinical Trials

Treating Brain Swelling in Pediatric Cerebral Malaria

TBS
Start date: January 8, 2018
Phase: Phase 3
Study type: Interventional

This study evaluates the effectiveness of two interventions in Malawian children with cerebral malaria at high risk of death. One-third of the participants will receive treatment as usual, one-third will receive treatment as usual and be placed on a mechanical ventilator, and one-third will receive treatment as usual plus intravenous hypertonic saline.

NCT ID: NCT03276494 Completed - Stroke Clinical Trials

Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access

Start date: April 21, 2017
Phase: Phase 2
Study type: Interventional

Hypertonic saline is used to treat elevated intracranial pressure. Intraosseous vascular access has been used to administer fluids and medications. This study combines these to administer 3% hypertonic saline via IO.

NCT ID: NCT03000283 Completed - Stroke Clinical Trials

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

Start date: March 22, 2017
Phase: Phase 1
Study type: Interventional

The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these same patients. This study is also an essential first step in understanding the role of conivaptan in CE management. Hypothesis: The frequent and early use of conivaptan at 40mg/day will be safe and well-tolerated, and also reduce cerebral edema, in patients with intracerebral hemorrhage and pressure.

NCT ID: NCT02937441 Completed - Cerebral Edema Clinical Trials

Evaluation of the Cerebral Edema in Children Having Diabetic Ketoacidosis

Start date: August 2016
Phase:
Study type: Observational

The purpose of this study is to determine cerebral edema with evaluation of measurement of diameter of optic nerve sheath.

NCT ID: NCT02701582 Completed - Surgery Clinical Trials

Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients

Start date: March 2014
Phase: N/A
Study type: Interventional

This is a prospective, randomized controlled trial to determine if using FloTrac/EV1000 system in neurosurgical patients undergoing craniotomies for aneurysm repair or tumor resection complicated by cerebral edema, or complex spinal surgery including multi-level scoliosis correction, is a more effective way of monitoring fluid.

NCT ID: NCT02594137 Completed - Clinical trials for Craniocerebral Trauma

A Comparison Between Two Techniques for Performing Decompressive Craniectomy

Start date: January 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two surgical techniques for a neurosurgical procedure used to treat cerebral edema (decompressive craniectomy): with watertight duraplasty vs. without watertight duraplasty (rapid closure decompressive craniectomy).